Low-dose Lucentis may help treat high-risk retinopathy of prematurity

Primary treatment of high-risk posterior retinopathy of prematurity with 0.2 mg Lucentis initially led to rapid and complete regression of the disease, with continued growth of normal-appearing retina peripherally, according to a case series.However, some degree of ROP recurrence in mid to anterior zone 2 was noted 8 to 11 weeks after injection in all eight eyes of the four infants.